Orion Oyj (ORINF)
USD 48.65
(0.0%)
USD 48.65
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 382.8 Million EUR | -5.51% |
| 2022 | 415.4 Million USD | 8.16% |
| 2021 | 384.07 Million EUR | -9.25% |
| 2020 | 423.22 Million EUR | 7.17% |
| 2019 | 394.89 Million EUR | 21.99% |
| 2018 | 323.7 Million EUR | 1.41% |
| 2017 | 319.2 Million EUR | -6.91% |
| 2016 | 342.9 Million EUR | -2.66% |
| 2015 | 352.28 Million EUR | 3.01% |
| 2014 | 342 Million EUR | -1.98% |
| 2013 | 348.9 Million EUR | -0.85% |
| 2012 | 351.9 Million EUR | 6.19% |
| 2011 | 331.4 Million EUR | 6.05% |
| 2010 | 312.5 Million EUR | 4.38% |
| 2009 | 299.4 Million EUR | 6.06% |
| 2008 | 282.3 Million EUR | 6.05% |
| 2007 | 266.2 Million EUR | 131.28% |
| 2006 | 115.1 Million EUR | -68.64% |
| 2005 | 367 Million EUR | -4.68% |
| 2004 | 385 Million EUR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 124.73 Million EUR | -3.43% |
| 2024 Q2 | 123.4 Million EUR | 7.09% |
| 2024 Q3 | 117.4 Million EUR | -5.17% |
| 2023 Q1 | 111.95 Million USD | -9.66% |
| 2023 FY | 392.5 Million EUR | -5.51% |
| 2023 Q4 | 132.11 Million EUR | 36.44% |
| 2023 Q3 | 96.82 Million USD | -20.6% |
| 2023 Q2 | 121.94 Million USD | 8.92% |
| 2022 Q3 | 110.25 Million EUR | 12.76% |
| 2022 FY | 415.4 Million USD | 8.16% |
| 2022 Q2 | 97.77 Million EUR | 4.69% |
| 2022 Q4 | 123.93 Million USD | 12.41% |
| 2022 Q1 | 93.4 Million EUR | -18.14% |
| 2021 Q4 | 114.1 Million EUR | 54.4% |
| 2021 Q1 | 93.67 Million EUR | -14.14% |
| 2021 Q2 | 105.54 Million EUR | 12.68% |
| 2021 Q3 | 73.9 Million EUR | -29.98% |
| 2021 FY | 384.07 Million EUR | -9.25% |
| 2020 Q3 | 78.3 Million EUR | -15.44% |
| 2020 Q1 | 89 Million EUR | -16.51% |
| 2020 Q2 | 92.6 Million EUR | 4.04% |
| 2020 FY | 423.22 Million EUR | 7.17% |
| 2020 Q4 | 109.1 Million EUR | 39.34% |
| 2019 Q2 | 98.1 Million EUR | 9.73% |
| 2019 Q1 | 89.4 Million EUR | -3.56% |
| 2019 FY | 394.89 Million EUR | 21.99% |
| 2019 Q4 | 106.6 Million EUR | 23.24% |
| 2019 Q3 | 86.5 Million EUR | -11.82% |
| 2018 FY | 323.7 Million EUR | 1.41% |
| 2018 Q4 | 92.7 Million EUR | 19.0% |
| 2018 Q3 | 77.9 Million EUR | -9.84% |
| 2018 Q2 | 86.4 Million EUR | 8.27% |
| 2018 Q1 | 79.8 Million EUR | -16.44% |
| 2017 Q4 | 95.5 Million EUR | 28.02% |
| 2017 Q3 | 74.6 Million EUR | -14.45% |
| 2017 Q2 | 87.2 Million EUR | 9.55% |
| 2017 Q1 | 79.6 Million EUR | -26.36% |
| 2017 FY | 319.2 Million EUR | -6.91% |
| 2016 Q3 | 59.6 Million EUR | -33.85% |
| 2016 Q4 | 108.1 Million EUR | 81.38% |
| 2016 Q1 | 79.4 Million EUR | -17.38% |
| 2016 Q2 | 90.1 Million EUR | 13.48% |
| 2016 FY | 342.9 Million EUR | -2.66% |
| 2015 Q3 | 75.2 Million EUR | -13.16% |
| 2015 FY | 352.28 Million EUR | 3.01% |
| 2015 Q4 | 96.1 Million EUR | 27.79% |
| 2015 Q2 | 86.6 Million EUR | 1.41% |
| 2015 Q1 | 85.4 Million EUR | -9.82% |
| 2014 Q3 | 74.4 Million EUR | -18.42% |
| 2014 Q1 | 81.8 Million EUR | -20.81% |
| 2014 Q4 | 94.7 Million EUR | 27.28% |
| 2014 FY | 342 Million EUR | -1.98% |
| 2014 Q2 | 91.2 Million EUR | 11.49% |
| 2013 Q1 | 83.4 Million EUR | -16.01% |
| 2013 FY | 348.9 Million EUR | -0.85% |
| 2013 Q2 | 88 Million EUR | 5.52% |
| 2013 Q4 | 103.3 Million EUR | 39.59% |
| 2013 Q3 | 74 Million EUR | -15.91% |
| 2012 FY | 351.9 Million EUR | 6.19% |
| 2012 Q1 | 82.1 Million EUR | -9.98% |
| 2012 Q4 | 99.3 Million EUR | 17.1% |
| 2012 Q3 | 84.8 Million EUR | -0.59% |
| 2012 Q2 | 85.3 Million EUR | 3.9% |
| 2011 Q1 | 78.5 Million EUR | -11.3% |
| 2011 Q3 | 72.9 Million EUR | -16.3% |
| 2011 Q4 | 91.2 Million EUR | 25.1% |
| 2011 FY | 331.4 Million EUR | 6.05% |
| 2011 Q2 | 87.1 Million EUR | 10.96% |
| 2010 Q3 | 71 Million EUR | -10.47% |
| 2010 Q4 | 88.5 Million EUR | 24.65% |
| 2010 Q1 | 73.7 Million EUR | -8.22% |
| 2010 FY | 312.5 Million EUR | 4.38% |
| 2010 Q2 | 79.3 Million EUR | 7.6% |
| 2009 Q2 | 77.9 Million EUR | 9.26% |
| 2009 FY | 299.4 Million EUR | 6.06% |
| 2009 Q4 | 80.3 Million EUR | 14.88% |
| 2009 Q3 | 69.9 Million EUR | -10.27% |
| 2009 Q1 | 71.3 Million EUR | 0.0% |
| 2008 FY | 282.3 Million EUR | 6.05% |
| 2007 FY | 266.2 Million EUR | 131.28% |
| 2006 FY | 115.1 Million EUR | -68.64% |
| 2005 FY | 367 Million EUR | -4.68% |
| 2004 FY | 385 Million EUR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| AstraZeneca PLC | 29.57 Billion USD | 98.706% |
| Bristol-Myers Squibb Company PFD CONV 2 | 17.07 Billion USD | 97.758% |
| CSPC Pharmaceutical Group Limited | 2.14 Billion USD | 82.17% |
| Clarus Therapeutics Holdings, Inc. | 50.96 Million USD | -651.045% |
| Novartis AG | 24.87 Billion USD | 98.461% |
| PT Kalbe Farma Tbk. | 11823.24 Billion USD | 99.997% |